Xbiome

Xbiome, established in 2017, operates at the intersection of artificial intelligence and microbiome-based therapeutics. The company was founded by Dr. Tan Yan, who serves as CEO, and Dr. Shi Yan, the Chief Scientific Officer. Dr. Tan's background includes a Ph.D. from Cornell University and experience at the Boston Consulting Group, while Dr. Shi brings expertise from his time as a postdoctoral researcher at the University of Pennsylvania and work at Johnson & Johnson, grounding the company's leadership in both business strategy and deep scientific knowledge.

The firm focuses on developing drugs by targeting the gut microbiome, which is implicated in a wide range of diseases. Xbiome's core is its proprietary platform, X-Evolution, which integrates AI, bioinformatics, and gut microbiome technologies to accelerate the discovery and development of new drugs. This data-driven approach aims to improve the success rate compared to traditional drug discovery paradigms. The company's business model revolves around the research, development, and eventual commercialization of these novel therapeutics.

Xbiome's product pipeline is advancing with several candidates in development. Its leading program, M-001, is designed to treat moderate to severe ulcerative colitis and has progressed to Phase II clinical trials in China and received IND clearance from the FDA in the United States. Another key candidate, M-007, an orally administered live biotherapeutic product, has also received FDA IND clearance for the treatment of acute GvHD. These milestones underscore the company's progress in translating its AI-driven research into tangible clinical assets targeting inflammatory and immune-related conditions.

Keywords: microbiome therapeutics, drug development, AI drug discovery, live biotherapeutics, gut health, ulcerative colitis, Graft-versus-Host Disease, bioinformatics, clinical trials, fecal microbiota transplantation